 Phase I Dose-finding study: The patients will be divided into 3 cohorts 15 patients per cohort, each cohort receiving a fixed metronomic thrice a week dose of oral vinorelbine at 60 mgweek, 90 mgweek, and 120 mgweek respectively. Each patient within each cohort will receive a starting dose of sorafenib at 200 mg bid for 4 weeks. In the absence of dose-limiting toxicities, the dose of sorafenib will be escalated to 400 mg bid for another 4 weeks, 600 mg bid for 4 weeks and then finally 800 mg bid. We should arrive at 3 different MTDs from the 3 cohorts. 